Novartis And Cohen: A View Into Pharma's Policy Concerns As Trump Took Office
Executive Summary
As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry was preparing for the debate it's eventually getting to have.
You may also be interested in...
Trump Tries To Shame A Defiant Pfizer On Drug Pricing
President Trump called out Pfizer’s recent price increases on Twitter July 9. Pfizer was one of only four companies that took a second round of price increases in 2018, according to analysts at Morgan Stanley. CEO Read has long defended the industry's pricing practices, even as public criticism of the high drug prices has grown.
Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?
How Drug Promotion Might Change Under Trump's Rx Pricing Plan
DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.